Last update June 29, 2020

Κλενβουτερόλη

Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

Long-acting bronchodilator such as salmeterol that, when inhaled, does not reach plasma in significant quantities.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data: low molecular weight, low protein binding and long half-life (Yang 2015) makes transfer to milk possible in amounts that could be significant.

Clenbuterol does not alter prolactin levels (Laakmann 1990).

Due to its long half-life, its potential toxicity and illegal uses in veterinary medicine and sports (Woolum 2020) it is not commercialized in several countries. and safer known alternatives are preferred, especially during the neonatal period and in case of prematurity.

Inhaled bronchodilator drugs are preferred because of a lower secretion into breast milk.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Κλενβουτερόλη is Clenbuterol Hydrochloride in Greek.

Is written in other languages:

Κλενβουτερόλη is also known as

Groups

Κλενβουτερόλη belongs to these groups or families:

Tradenames

Main tradenames from several countries containing Κλενβουτερόλη in its composition:

List of 17 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 89 - 98 (oral) %
Molecular weight 314 daltons
Protein Binding 50 %
pKa 14.1 -
Tmax 2.4 ± 0.9 hours
T½ 33.2 ± 9.7 hours

References

  1. Woolum J, Mancuso N, Rutter PW, Baum RA, Akpunonu P. Chomping at the Bit: A Descriptive Report on Pediatric Clenbuterol Ingestion. J Pharm Pract. 2020 Jun;33(3):386-389. Abstract
  2. Yang YG, Song LX, Jiang N, Xu XT, Di XH, Zhang M. Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers. Int J Clin Exp Med. 2015 Oct 15;8(10):18744-50. eCollection 2015. Abstract
  3. Laakmann G, Munz T, Hinz A, Voderholzer U. Influence of clenbuterol, a beta-adrenergic agonist, on desipramine induced growth hormone, prolactin and cortisol stimulation. Psychoneuroendocrinology. 1990;15(5-6):391-9. Abstract
  4. Yamamoto I, Iwata K, Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. J Pharmacobiodyn. 1985 Abstract

Total visits

1,133

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM